

Impulse oscillometry versus spirometry in a long-term study of controller therapy for pediatric asthma

Gary L. Larsen, MD,^a Wayne Morgan, MD,^g Gregory P. Heldt, MD,^e David T. Mauger, PhD,^d Susan J. Boehmer, MA,^d Vernon M. Chinchilli, PhD,^d Robert F. Lemanske, Jr, MD,^c Fernando Martinez, MD,^g Robert C. Strunk, MD,^b Stanley J. Szeffler, MD,^a Robert S. Zeiger, MD, PhD,^{e,f} Lynn M. Taussig, MD,^a Leonard B. Bacharier, MD,^b Theresa W. Guilbert, MD,^c Shelley Radford,^{g,†} and Christine A. Sorkness, PharmD,^c for the Childhood Asthma Research and Education Network of the National Heart, Lung, and Blood Institute *Denver, Colo, St Louis, Mo, Madison, Wis, Hershey, Pa, San Diego and Pasadena, Calif, and Tucson, Ariz*

Background: Determination of the benefits and limitations of specific physiologic tests has not been well studied in long-term clinical pediatric trials.

Objective: We sought to determine the utility of impulse oscillometry in a long-term comparison of 3 controller regimens in children with persistent asthma.

Methods: Children 6 to 14 years of age with mild-to-moderate persistent asthma were characterized with oscillometry and spirometry before entry into a clinical trial and then serially during 48 weeks of therapy with either an inhaled corticosteroid, a combination inhaled corticosteroid with a long-acting β -agonist, or a leukotriene receptor antagonist.

Results: The FEV₁/forced vital capacity ratio, as well as the forced expiratory flow from 25% to 75% of forced vital capacity in terms of spirometric parameters and the reactance area (XA) from impulse oscillometry, appeared to complement information provided by FEV₁ when comparing the tests and factors that appeared to predict a response to treatment. XA was unique in that it, as distinct from spirometric variables, reflected ongoing improvement during the latter part of the trial. In general, improvements in XA during the latter part of the study occurred independently of indices of atopy and the level of airway responsiveness.

Conclusion: Assessment of respiratory mechanics over time with oscillometry might offer additional insights into the response of asthmatic patients to therapy. In particular, the pattern of improvement seen in XA over the course of therapy suggests this test might detect alterations in airway mechanics not reflected by spirometry. The possibility that changes in XA reflect ongoing improvement in small airway function deserves additional study. (*J Allergy Clin Immunol* ■■■■;■■■:■■■-■■■.)

Key words: Pediatric asthma, impulse oscillometry, spirometry, therapy of asthma

The ability to easily evaluate respiratory function in children with asthma is of central importance in terms of following the course of the disease. This is especially important when tracking the effects of therapy.¹ With respect to asthma clinical research, physiologic tests are commonly used to define the effects of intervention. Although a variety of tests can be used, values obtained from spirometry are most commonly reported due in part to the large volume of information on the use of tests such as FEV₁ measurement. However, this approach might have limitations. For example, spirometric tests might be less helpful than other measures of respiratory function when assessing airway lability in preschool children at risk for persistent asthma.² Thus the issue of

From ^athe Department of Pediatrics, National Jewish Health, Denver; ^bthe Department of Pediatrics, Washington University School of Medicine, St Louis; ^cthe University of Wisconsin Clinical Science Center, University of Wisconsin School of Medicine, Madison; ^dthe Department of Public Health Sciences, Pennsylvania State University, Hershey; ^ethe Department of Pediatrics, the University of California San Diego Medical Center, San Diego; ^fthe Department of Allergy, Kaiser Permanente Southern California Region, Pasadena; and ^gthe Arizona Respiratory Center, University of Arizona College of Medicine, Tucson.

[†]Deceased.

Supported by grants U10HL064287, U10HL064288, U10HL064295, U10HL064305, and U10HL064307 from the National Heart, Lung, and Blood Institute. This study was carried out in part in the General Clinical Research Centers at National Jewish Medical and Research Center (M01 RR00051), Washington University School of Medicine (M01 RR00036), and the University of Wisconsin (M01 RR03186).

Disclosure of potential conflict of interest: G. L. Larsen is on the Asthma Advisory Board for Genentech and receives grant support from the National Institutes of Health. V. M. Chinchilli receives grant support from the National Heart, Lung, and Blood Institute. R. F. Lemanske is on the speakers' bureau for Merck, is a consultant for GlaxoSmithKline, and receives grant support from the National Heart, Lung, and Blood Institute. F. Martinez is on the Advisory Boards for Merck and MedImmune, receives lecture fees from Merck and Pfizer, and is a consultant for GlaxoSmithKline and Pfizer. S. J. Szeffler is a consultant for AstraZeneca, GlaxoSmithKline, Aventis,

Genentech, and Merck and receives grant support from the National Institutes of Health; the National Heart, Lung, and Blood Institute; and Ross Pharmaceuticals. R. S. Zeiger is a consultant for Aerocrine, AstraZeneca, Dynavax, Genentech, Merck, Novartis, and GlaxoSmithKline and receives grant support from Sanofi-Aventis, Teva Pharmaceuticals, Merck, AstraZeneca, GlaxoSmithKline, and Genentech. L. B. Bacharier receives honoraria from AstraZeneca, Genentech, GlaxoSmithKline, Merck, and Aerocrine and is on the Advisory Board for Schering-Plough. T. W. Guilbert receives honoraria from GlaxoSmithKline, AstraZeneca, the Peerpoint Medical Education Institute, Merck, Schering-Plough, Genentech/Novartis, and Antidote; receives grant support from Altus Pharmaceuticals, Inspire Pharmaceuticals, the National Institutes of Health, and the National Heart, Lung, and Blood Institute; and is a member of the American Lung Association, American Thoracic Society, and American Academy of Pediatrics. C. A. Sorkness is a consultant and on the speakers' bureau for GlaxoSmithKline and receives grant support from Pharmaxis. The rest of the authors have declared that they have no conflict of interest.

Received for publication May 13, 2008; revised October 13, 2008; accepted for publication October 20, 2008.

Reprint requests: Gary L. Larsen, MD, Department of Pediatrics, National Jewish Health, 1400 Jackson St, Denver, CO 80206. E-mail: larseng@njc.org. 0091-6749/\$34.00

© 2008 American Academy of Allergy, Asthma & Immunology
doi:10.1016/j.jaci.2008.10.036

Abbreviations used

CARE: Childhood Asthma Research and Education Network
 eNO: Exhaled nitric oxide
 FEF₂₅₋₇₅: Forced expiratory flow from 25% to 75% of forced vital capacity
 Fres: Resonant frequency
 FVC: Forced vital capacity
 IOS: Impulse oscillometry
 NHLBI: National Heart, Lung, and Blood Institute
 PACT: Pediatric Asthma Controller Trial
 R5, R10: Resistance of the respiratory system at 5 and 10 Hz
 XA: Reactance area

what physiologic tests will be most informative in long-terms studies requires evaluation.

Forced oscillation is one of several techniques that have been used to obtain measures of respiratory function in subjects with lung disease.^{3,4} This method involves the application of pressure waves to the airway opening through a mouthpiece and measurement of respiratory system impedance from which resistance and reactance can be derived.⁵ Results from studies to date suggest a reasonable agreement with more traditional measures of lung function in children with asthma.⁶ In this respect there are reports of use of this technique in young children with acute asthma.^{7,8} This technique has also been used to quantify the response to methacholine^{6,7,9,10} and histamine⁹ challenges in young asthmatic subjects. The results of these and other studies, as reviewed by Oostveen et al³ and Goldman,⁵ suggest that forced oscillation might have advantages when evaluating acute responses to therapy and might also prove useful in following the course of the disease.

The focus of this work is on a comparison of spirometric measures with values obtained by means of impulse oscillometry (IOS) as methods to follow the course of children with asthma who have been treated in different ways. The latter is a forced oscillation technique that involves application of a rectangular pulse signal to the airways.¹¹ Subjects assessed were participants in the Pediatric Asthma Controller Trial (PACT).¹² This study included a cohort of children with mild-to-moderate persistent asthma enrolled to compare the effectiveness of 3 treatment regimens in achieving asthma control. Performance of spirometry and IOS before, during, and at the end of the trial allowed comparison of different ways of monitoring respiratory function over a prolonged period of therapy.

METHODS**Study population**

The study population for the PACT has been described.¹² Briefly, children with asthma 6 to less than 14 years of age were screened, characterized, and randomized at 5 clinical centers of the Childhood Asthma Research and Education (CARE) Network funded by the National Heart, Lung, and Blood Institute (NHLBI). The PACT was designed to compare the effectiveness of 3 treatment regimens in achieving asthma control in school-aged children with mild-to-moderate persistent asthma. Inclusion criteria included physician-diagnosed asthma, the ability to perform reproducible spirometry, and an FEV₁ (measured >4 hours since use of a bronchodilator) of at least 80% of the predicted normal value at screening and at least 70% of predicted value at randomization. Each child had airway lability, as defined by methacholine responsiveness with a PC₂₀ value of 12.5 mg/mL or less (see below). Exclusion criteria included systemic corticosteroid use within 4 weeks before enrollment.

Two or more hospitalizations or 4 or more courses of systemic corticosteroids in the past year also precluded participation. A listing of inclusion and exclusion criteria has been presented.¹² Informed consent consisted of signing a copy of the consent form approved by the institutional review board of the subject's respective study institution. Assent from the child was also obtained.

Protocol

All participants had mild-to-moderate persistent asthma, as defined by diary-reported symptoms, β -agonist use, or peak flows obtained during the final week of a 2- to 4-week run-in period. After the run-in period, participants were assigned to one of 3 treatment arms: 100 μ g of fluticasone in the morning and 100 μ g of fluticasone in the evening (Flovent Diskus; GlaxoSmithKline, London, United Kingdom) plus oral placebo in the evening (fluticasone monotherapy); 100 μ g of fluticasone/50 μ g of salmeterol (Advair Diskus, GlaxoSmithKline) in the morning and 50 μ g of salmeterol (Serevent Diskus, GlaxoSmithKline) in the evening plus oral placebo in the evening (PACT combination); or placebo Diskus in the morning and placebo Diskus in the evening plus 5 mg of montelukast (Singulair; Merck, Whitehouse Station, NJ) in the evening (montelukast monotherapy). Treatment assignment followed a double-blind, randomized, parallel-group design stratified by center.

Pulmonary function testing: spirometry and IOS

Spirometry and IOS were performed by CARE-certified technicians, with overreading performed to insure quality control. The tests were performed with a pneumotachograph-type spirometer interfaced with a personal computer system (Jaeger-Toennies GmbH, Hoechberg, Germany). Equipment and testing procedures for the maximal expiratory flow volume maneuvers met American Thoracic Society 1994 spirometry standards,^{13,14} with techniques modified for children less than 8 years of age, as described by Eigen et al¹⁵ and Arets et al.¹⁶ Age-, sex-, and ethnicity-appropriate prediction equations were used to calculate percent predicted values for spirometric parameters.¹⁷

IOS was performed by applying a rectangular pulse signal to airways with a pressure step wave every 250 ms through a loudspeaker to the airway opening by means of a mouthpiece through which the subjects breathed normally (tidal breathing) for 30 seconds at a time (see below). The subject wore a nose clip during sampling, with the subject or parent/guardian gently holding the sides of the face to decrease the shunt compliance of the cheeks. Repeated measurements took a few minutes to perform, with at least 3 IOS procedures performed both before and after bronchodilator. Measurements were made by using commercially available equipment (Master Screen; E. Jaeger, Würzburg, Germany) and were processed on a Dell computer. Measurements were carried out during stable tidal breathing over a 30-second interval of time, with the indices obtained being the total respiratory resistance and reactance as a function of frequency. The former was calculated from pressure and flow signals in which pressure was in phase with flow, and the latter computation involved pressure out of phase with flow. Reactance at low frequencies reflects the pressures needed to overcome the viscoelastic properties of the lung. In addition to resistance and reactance, the resonant frequency (Fres) was recorded. This is the frequency at which reactance is zero. Also recorded was the reactance area (XA), an integrated response index for reactance developed by Goldman⁵ reflecting the integral of the negative values of reactance from 5 Hz to Fres. This value might in part reflect small airway function. The duration of each measurement was 30 seconds, yielding a total of 120 impulses from which the mean values of resistance and reactance were calculated at discrete frequencies from 5 to 35 Hz. During data acquisition, pressure and flow traces were graphically displayed in real time. Measurements were accepted when the tracings showed uninterrupted breathing during data acquisition. Measurements were rejected if disturbed by coughing, breath holding, swallowing, or vocalization. The values from 3 acceptable 30-second periods of data collection were averaged in terms of IOS parameters. The value of R10 was monitored to assess repeatability of the 30 seconds of data collection. The coherence values at 10 Hz had to be 0.80 or greater, whereas values of R10 had to be within a 20% range (calculated from the largest value for R10). Predicted values for resistance of the respiratory system at 5 and 10 Hz (R5 and R10), reactance of the respiratory system at 5 Hz, and Fres are from




FIG 1. Changes in FEV_1 (A), FEV_1/FVC ratio (B), FEF_{25-75} (C), and XA (D) over time are displayed for 3 treatment groups as both mean data at each measurement point (dashed lines) and as a regression model with a change point at 12 weeks (solid lines). The statistical analyses using the regression model are summarized in Tables I and II. Over the first 12 weeks of therapy, the slopes for FEV_1 , FEV_1/FVC ratio, and FEF_{25-75} were significant in a positive direction for combination and fluticasone therapy. However, for these spirometric parameters, the pattern over the last period of therapy (12–48 weeks) was different, with all slopes close to zero. Conversely, XA significantly improved in the fluticasone group during the latter period, as reflected by the negative slope for change in XA. *Pre-BD*, Before bronchodilator.

Lechtenböcker et al (unpublished communication) based on 614 healthy children and adolescents from 5 to 17 years of age. These values represent the default normal reference values for the equipment used in this study. For XA, normal values for children of the age range used in this study have not been established. Thus the latter is reported as an absolute value with changes tracked over the course of the study. For XA, improvement is reflected by a decrease in this value.

Methacholine challenge

A CARE-certified technician measured airway responsiveness based on the decrease in FEV_1 after administering increasing concentrations of methacholine (Provocholine; Methapharm, Coral Springs, Fla). This drug was delivered through the small-volume nebulizer–tidal breathing technique (Wright nebulizer; Medi-tech Ltd, Montreal, Quebec, Canada), according to a standardized procedure¹⁸ and American Thoracic Society 2000 methacholine challenge testing guidelines.¹⁹ The test was performed at least 4 hours after the last use of a short-acting bronchodilator, caffeine consumption, or both and at least 4 weeks after the last oral corticosteroid use or respiratory tract infection. Baseline FEV_1 values equaled or exceeded 70% of predicted values before the test. A diluent step was performed and used as the reference value for calculation of PC_{20} .

Measurement of biomarkers

Exhaled nitric oxide (eNO) was measured by using the online technique recommended by the American Thoracic Society²⁰ with the NIOX system (Aerocrine AB, Stockholm, Sweden). This technique is described by Strunk et al.²¹ Measurement of eNO was obtained before spirometry. Peripheral blood eosinophil counts were obtained by means of automated assay at each center. Immediate hypersensitivity skin tests were performed with 8 common aeroallergens, as outlined previously.²¹ Testing was performed in accordance with a study-specific protocol.^{22,23}

Statistical analysis

Given the time course and pattern of the responses to therapy in terms of FEV_1 and FEV_1 /forced vital capacity (FVC) ratio, as reported in the PACT¹² and reproduced in part in Fig 1, A and B, a regression model with a change point at 12 weeks was used to describe changes in lung function over time. The term *change point* refers to the time at which the temporal profile of the outcome changes. In this case the form of the regression model is a straight line from time zero to 12 weeks connected to another straight line extending from 12 to 48 weeks (Fig 1, regression model shown by straight lines with change point at 12 weeks). All outcomes were defined in terms of change from baseline, and thus the regression line begins at zero on the y-axis. The

TABLE I. Slopes for tests of lung function in the first 12 weeks and from 12 to 48 weeks of treatment

Lung function	Time	Treatment	Estimate (95% CI)	P value
FEV ₁	0-12 wk	Combination	0.320 (0.201 to 0.439)	<.0001
		Fluticasone	0.596 (0.477 to 0.715)	<.0001
		Montelukast	-0.011 (-0.128 to 0.107)	.8589
	12-48 wk	Combination	-0.028 (-0.096 to 0.039)	.4138
		Fluticasone	-0.039 (-0.105 to 0.027)	.2483
		Montelukast	-0.028 (-0.094 to 0.038)	.4010
FEV ₁ /FVC	0-12 wk	Combination	0.225 (0.135 to 0.315)	<.0001
		Fluticasone	0.375 (0.287 to 0.463)	<.0001
		Montelukast	0.015 (-0.071 to 0.101)	.7323
	12-48 wk	Combination	-0.036 (-0.086 to 0.015)	.1693
		Fluticasone	0.006 (-0.043 to 0.055)	.8140
		Montelukast	-0.022 (-0.070 to 0.026)	.3753
FEF ₂₅₋₇₅	0-12 wk	Combination	0.686 (0.461 to 0.910)	<.0001
		Fluticasone	0.902 (0.671 to 1.134)	<.0001
		Montelukast	-0.245 (-0.477 to -0.012)	.0393
	12-48 wk	Combination	-0.107 (-0.235 to 0.022)	.1044
		Fluticasone	0.042 (-0.087 to 0.171)	.5238
		Montelukast	0.040 (-0.090 to 0.169)	.5483
XA	0-12 wk	Combination	-0.893 (-1.544 to -0.242)	.0073
		Fluticasone	-0.256 (-0.889 to 0.378)	.4293
		Montelukast	-0.047 (-0.697 to 0.603)	.8876
	12-48 wk	Combination	-0.116 (-0.484 to 0.253)	.5394
		Fluticasone	-0.656 (-1.008 to -0.303)	.0003
		Montelukast	-0.088 (-0.451 to 0.274)	.6325

slope of the line from baseline to 12 weeks represents the initial response to treatment, whereas the slope of the line from 12 to 48 weeks represents later changes after the initial response.

The regression models were fit within the framework of repeated-measures analysis for longitudinal data.²⁴ The results of the regression models are presented as population averages unadjusted for other covariates. Residual analysis was performed to verify that the model was appropriate for the data. All analyses were performed with SAS version 9.2 statistical software (SAS Institute, Inc, Cary, NC). Significance was established at a *P* value of less than .05 (2-tailed).

Protocol review

An institutional review board at each center plus an NHLBI Protocol Review Committee and an NHLBI Data Safety Monitoring Board approved the PACT protocol. The latter committees were formed specifically for the CARE Network.

RESULTS

Demographics/clinical characteristics of study participants

Demographic characteristics were presented by Sorkness et al.¹² Of the 285 randomized subjects, 252 completed the study. The 3 treatment groups were well matched, with characteristics at baseline of mild-to-moderate asthma. Of the scheduled visits, 97% were completed. Adherence to study medications was high, as presented in the main outcome article.¹² In terms of the primary outcome (asthma control days), fluticasone monotherapy and PACT combination therapy were comparable and superior to montelukast.

Spirometry and IOS results

As presented in the original manuscript, prebronchodilator FEV₁ (percent predicted) and FEV₁/FVC ratio (expressed as a

percentage) increased significantly more with fluticasone monotherapy than with the PACT combination and montelukast monotherapy. The mean change in FEV₁ percent predicted from baseline was 6.32% with fluticasone monotherapy and 3.62% with the PACT combination, whereas the mean change for FEV₁/FVC ratio was 3.95% and 1.76%, respectively. Montelukast did not improve these measures of lung function.

The results of fitting the FEV₁ and FEV₁/FVC ratio data to the change-point model are shown in Fig 1. The associated parameter estimates are summarized in Tables I and II. The parameter estimates represent the changes in FEV₁ and FEV₁/FVC ratio per week. The *P* values reported in Table I are those associated with testing whether the slope parameter for each treatment is different from zero. The *P* values in Table II are those associated with testing whether the treatments have equal slopes. Over the first 12 weeks of therapy, the slopes for these measures of airways obstruction were significant in a positive direction for combination and fluticasone therapy (Table I), with all groups differing from the 2 others (Table II). However, the pattern over the last period of therapy (12-48 weeks) was different. Slopes for both tests of lung function were close to zero, with the probabilities not significant. Thus these measures of lung function improved initially in 2 of the 3 treatment arms and then were fairly static for the remainder of the study.

Changes over time for forced expiratory flow from 25% to 75% of FVC (FEF₂₅₋₇₅, expressed as percent predicted) for all 3 treatment groups are shown in Fig 1, C. The statistical analysis in terms of the slopes and comparisons between groups is presented in Tables I and II, respectively. Over the first 12 weeks of therapy, the slopes for this measure of airways obstruction were significant in a positive direction for combination and fluticasone therapy (Table I) and significant in a negative direction for the montelukast group. During this initial period of treatment, the groups receiving combination and fluticasone therapy were significantly different from the group receiving montelukast (Table II). Once

TABLE II. Differences in slopes for tests of lung function in the first 12 weeks and from 12 to 48 weeks of treatment

Lung function	Time	Treatment	Estimate (95% CI)	P value
FEV ₁	0-12 wk	C vs F	-0.275 (-0.443 to -0.107)	.0014
		C vs M	0.331 (0.164 to 0.499)	.0001
		F vs M	0.606 (0.439 to 0.774)	<.0001
	12-48 wk	C vs F	0.011 (-0.084 to 0.105)	.8247
		C vs M	0.000 (-0.094 to 0.094)	.9988
		F vs M	-0.011 (-0.104 to 0.083)	.8237
FEV ₁ /FVC	0-12 wk	C vs F	-0.150 (-0.276 to -0.024)	.0199
		C vs M	0.210 (0.086 to 0.335)	.0010
		F vs M	0.360 (0.237 to 0.483)	<.0001
	12-48 wk	C vs F	-0.041 (-0.112 to 0.029)	.2489
		C vs M	-0.014 (-0.084 to 0.056)	.7008
		F vs M	0.028 (-0.041 to 0.096)	.4292
FEF ₂₅₋₇₅	0-12 wk	C vs F	-0.217 (-0.539 to 0.106)	.1887
		C vs M	0.930 (0.607 to 1.254)	<.0001
		F vs M	1.147 (0.819 to 1.475)	<.0001
	12-48 wk	C vs F	-0.149 (-0.331 to 0.033)	.1099
		C vs M	-0.146 (-0.329 to 0.036)	.1162
		F vs M	0.002 (-0.180 to 0.185)	.9803
XA	0-12 wk	C vs F	-0.637 (-1.546 to 0.271)	.1694
		C vs M	-0.846 (-1.766 to 0.074)	.0717
		F vs M	-0.209 (-1.116 to 0.699)	.6522
	12-48 wk	C vs F	0.540 (0.030 to 1.050)	.0382
		C vs M	-0.027 (-0.544 to 0.490)	.9184
		F vs M	-0.567 (-1.073 to -0.062)	.0281

C, Combination; F, fluticasone; M, montelukast.

again, the pattern over the last period of therapy (12-48 weeks) was different. Slopes were close to zero, with the probabilities not significant. Thus FEF₂₅₋₇₅ improved initially in 2 of the 3 treatment arms and then was fairly static for the duration of the study for all treatment arms.

For XA, the patterns of change over time were different than those seen with spirometric parameters. The changes in absolute value of XA for the 3 treatment groups are shown graphically in Fig 1, D, whereas the slopes and their estimates for the first and second phases of treatment are listed in Table I. During the initial 12 weeks of therapy, the only group in which the slope was significantly different than zero was the one receiving combination therapy. During the subsequent 36 weeks of treatment, the group receiving fluticasone showed significant improvement, as reflected by the negative slope for change in XA over time (Table I), with the differences between the fluticasone group and the other 2 groups being significant (Table II).

Relationship of biomarkers and level of reactivity to changes in XA

The possibility of correlations existing between potential biomarkers of disease and the variable (XA) that improved with fluticasone therapy during the latter part of the study was also addressed. Listed in Table E1 of this article's Online Repository (available at www.jacionline.org) are the slopes of XA during the latter part of therapy for subjects treated with fluticasone. The subjects were divided into those with eNO values of less than 25 parts per billion (ppb) versus those with values of 25 ppb or higher, subjects with negative versus those with positive skin test results, and participants with eosinophil percentages in their blood counts of less than 4% versus those with values of 4% and higher. As listed in Table E1, the slope estimates and the probabilities were comparable in all groups, with the exception of the grouping taking into consideration eosinophil

percentages in blood. In this analysis those that would be considered to have a biomarker compatible with more active disease had a slope estimate that was significant. When eNO or skin test reactivity was used to define the subgroupings, statistical significance was found, regardless of eNO levels or whether the subjects had reactions to aeroallergens.

In addition to the 3 biomarkers, the subjects receiving fluticasone were also assessed in terms of slope estimates and probabilities depending on their methacholine responsiveness. For this analysis, subjects were divided into those with a PC₂₀ of less than 2.0 mg/mL and those with a value equal to or greater than 2.0 mg/mL. As seen in Table E1, the *P* values were both significant. The slope estimates and the probabilities were greater in the group that was less reactive in terms of methacholine responsiveness.

DISCUSSION

Assessment of lung function with IOS was easily accomplished in children with persistent asthma who were 6 to 14 years of age. This study found one IOS parameter (XA) demonstrated continued improvement over a prolonged period of time compared with spirometric variables. As such, IOS might offer a valuable adjunct to spirometry in following the course of subjects enrolled in clinical studies. In terms of biomarkers, a higher level of circulating eosinophils identified subjects more likely to respond in terms of improvements in XA with inhaled corticosteroid therapy. Increased eNO values, skin test reactivity to aeroallergens, and level of airway responsiveness did not distinguish those with improvements in XA.

The value of assessing objective measures of lung function that include spirometric parameters in children with asthma is well established. For example, Bye et al²⁵ argued that failure to perform spirometry in children with asthma results in underdiagnosis of airflow obstruction. More recently, Fuhlbrigge et al²⁶

demonstrated a strong association between FEV_1 expressed as a percentage of predicted value and the risk of an asthma attack over the subsequent year. In terms of clinical research in asthma, spirometric variables are commonly used to define entry criteria and to gauge the effects of intervention. However, use of FEV_1 might have limitations in terms of both clinical care and research. In this respect the question has been raised about whether FEV_1 is the best spirometric measure of severity in childhood asthma.^{27,28} Thus the issue of what physiologic tests other than FEV_1 will be of use in following the course of subjects with persistent asthma over a prolonged period of treatment was a focus of this work.

The design of the PACT provided a unique opportunity to compare methods of physiologically characterizing school-age children with persistent asthma over time when they were treated with 3 distinct medical regimens. These children were characterized by respiratory physiology, symptom burden, and methacholine responsiveness. The study design also allowed assessment of biomarkers in subjects so that changes in physiologic measurements could be compared with markers of disease activity when therapy began.

In terms of spirometry, we focused on FEV_1 , as well as FEV_1/FVC ratio and FEF_{25-75} , for reasons given previously. Although the initial report of the results of this study focused on both FEV_1 and FEV_1/FVC ratio,¹² we believed it important to address the changes over time in more detail with a random-effects model that addresses both acute and more chronic changes over time. Our focus in this analysis on FEF_{25-75} was based on the argument that this test, as well as FEV_1/FVC ratio, might more accurately measure lung function impairment than FEV_1 in children. The former parameter (FEF_{25-75}) has been believed to possibly reflect small airway function,^{29,30} and this also had appeal in terms of our analysis. XA, which reflects the integrated sum of the negative reactance values below the F_{res} , is also believed to reflect at least in part peripheral airway function.^{5,31} Thus our analysis yielded information on spirometric variables that might be useful in gauging a response but also on a spirometric parameter, as well as an IOS parameter, that might reflect events within more peripheral airways.

Our analysis of these tests of lung function demonstrated important trends in terms of therapeutic responses. For FEV_1 , as well as FEV_1/FVC ratio and FEF_{25-75} , significant changes in slopes were limited to the first 12 weeks of therapy, with the improvements maintained but not significantly increasing over the latter part of treatment. The improvements were seen in the groups receiving fluticasone monotherapy and combination therapy. For XA, the pattern was different. For this test, only the group receiving combination therapy exhibited a change in slope that was significantly different from zero in the initial 12 weeks of treatment. In addition, during the subsequent 36 weeks of treatment, the group receiving fluticasone showed significant improvement, as reflected by the negative slope of XA over time (Table I), with the differences between the fluticasone group and the other 2 groups being significant (Table II).

Comment is necessary regarding the changes that occur in XA over time when the results are expressed in absolute units rather than as a percentage of predicted value. This IOS parameter is a reflection of both the F_{res} and reactance of the respiratory system at 5 Hz. Both parameters normally decrease with growth, and thus XA is also expected to normally decrease in value over time with linear growth. However, as noted previously, predicted values of XA for children over the range of ages and heights used in this study are not available. Thus we elected to use absolute

values instead of extrapolated normal values from other data sets. With this approach, one must ask whether the changes seen with fluticasone therapy only reflect changes that occur with growth over the period of study. This is unlikely for several reasons. First, as reported by Sorkness et al,¹² differences among the 3 therapies in this study in terms of growth effects were not significant, including when stratified for age. Comparable growth was seen in all 3 treatment groups over the course of treatment, ranging from a mean of 5.3 cm in the fluticasone monotherapy and combination therapy groups to 5.7 cm in the montelukast monotherapy group. Second, during the last 36 weeks of treatment, the group receiving fluticasone showed not only a significant improvement as reflected by the negative slope for change in XA over time (Table I) but also a significant difference in slope when compared with the other 2 groups (Table II). Third, if stature had been significantly impaired in the groups receiving inhaled corticosteroids, changes in XA values over time would be expected to be less and not greater in magnitude. Therefore for these reasons, we believe that the changes in XA over time in the corticosteroid monotherapy group reflect more than just alterations that normally occur with growth.

Both FEF_{25-75} and XA might reflect events within more peripheral airways. Yet these 2 measures differed in terms of the patterns of improvement seen during the study. This was especially evident in terms of the improvement seen with corticosteroid monotherapy for XA but not FEF_{25-75} during the latter part of therapy. Thus XA might be more sensitive to alterations in peripheral airway function. Another possibility is that the improvement in XA over time reflects not only small airway function but also other mechanical events within the lung. Unfortunately, other tests of airway function that might shed light on this issue were not part of this study. More information on what is occurring over time in terms of air trapping, as reflected by the residual volume and ratio of residual volume to total lung capacity, might be helpful. Use of quantitative computed tomography might also help assess events within peripheral airways.³⁰

In older children, the CARE Network has previously reported that treatment of mild-to-moderate asthma in subjects 6 to 17 years of age with an inhaled corticosteroid led to not only improvement in spirometric results but also to significant improvement in R5 and XA.³² Although resistance measures at various frequencies, including R5 and R10, were obtained by means of IOS during the PACT and analyzed as part of this work, the changes were not of similar magnitude or as consistent as those seen with XA (CARE Network, unpublished observations). Thus we focused on XA alone for this report.

Biomarkers that reflect an atopic state have been used to determine whether they help predict the response to therapy. In another CARE Network study, a favorable response (in terms of FEV_1) to 8 weeks of fluticasone therapy was associated with higher baseline (pretreatment) levels of eNO, total eosinophils counts, and levels of serum IgE.³³ In terms of biomarkers used in the PACT, only peripheral eosinophil percentages identified subjects more likely to respond in terms of improvements in XA with inhaled corticosteroid therapy. Improvements in XA were seen regardless of eNO levels and skin test responses. Improvements in XA also occurred independently of the level of airway responsiveness. This observation also differed from the previous study, in which improvement in FEV_1 was associated with an initially lower PC_{20} value (greater airway reactivity) to methacholine.³³ These observations suggest that improvements

seen in XA with corticosteroid therapy over time might reflect effects that occur independent of atopy.

These data suggest that IOS might be informative in longer-term studies and might reflect improvements in lung function not reflected by spirometric parameters. This latter concept is supported by other studies. In adults with asthma, Evans et al³⁴ suggested that IOS is a more sensitive measure of change in airway function than spirometry when assessing the response to room-temperature and cold-temperature exercise challenges. In older children with asthma, Goldman et al³⁵ found significant differences in some IOS parameters (including both R5 measured during inspiration and XA) but not spirometric indices when assessing adolescents daily over a period of 3 days. In preschool children Marotta et al² reported that IOS responses to bronchodilator demonstrated significantly greater change than observed with FEV₁ in those 4-year-old children most likely to have persistent asthma. Conventional spirometry did not establish similar statistically significant findings. Thus IOS might provide a useful diagnostic tool when monitoring for the development of early asthma. In addition, IOS might also be helpful in obtaining objective outcome measures in studies of early intervention when spirometric measures are not as easily obtained.³⁶ Both issues require additional study in preschool children with wheezing that might progress to chronic asthma.³⁷

In summary, analysis of the response of PACT participants to an inhaled corticosteroid, combination therapy, and a leukotriene receptor antagonist by using IOS was feasible and revealed differences in the time course of improvement compared with spirometric variables. Additional investigations to define the benefits and limitations of this method of physiologic assessment over prolonged periods of time appear justified. In addition, additional study to address the possibility that the changes seen in XA in this study reflected continuing improvement in small airway function deserves attention.

Clinical implications: Assessment of respiratory mechanics over time with IOS might offer important information about the pulmonary response of asthmatic patients to therapy that is not reflected by spirometric parameters.

REFERENCES

- Larsen GL, Kerby GS, Guilbert TW, Morgan WJ. Functional assessment of asthma. In: Leung DYM, Sampson HA, Geha RS, Szefer SJ, editors. *Pediatric allergy: principles and practice*. St. Louis: Mosby; 2003. p. 357-65.
- Marotta A, Klennert MD, Price MR, Larsen GL, Liu AH. Impulse oscillometry provides an effective measure of lung dysfunction in 4-year-old children at risk for persistent asthma. *J Allergy Clin Immunol* 2003;112:317-22.
- Oostveen E, MacLeod D, Lorino H, Farré R, Hantos Z, Desager L, et al. The forced oscillation technique in clinical practice: methodology, recommendations and future developments. *Eur Respir J* 2003;22:1026-41.
- Desager KN, Marchal F, van de Woestijne KP. Forced oscillation technique. In: Stocks J, Sly PD, Tepper RS, Morgan WJ, editors. *Infant respiratory function testing*. New York: Wiley-Liss; 1996. p. 355-78.
- Goldman MD. Clinical application of forced oscillation. *Pulm Pharm Ther* 2001;14:341-50.
- Duiverman EJ, Neijens HJ, van der Snee-van Smaalen M, Kerribijn KF. Comparison of forced oscillometry and forced expirations for measuring dose-related responses to inhaled methacholine in asthmatic children. *Bull Eur Physiopathol Respir* 1986;22:433-6.
- Klug B, Bisgaard H. Measurement of lung function in awake 2-4-year-old asthmatic children during methacholine challenge and acute asthma: a comparison of the impulse oscillation technique, the interrupter technique, and transcutaneous measurement of oxygen versus whole-body plethysmography. *Pediatr Pulmonol* 1996;21:290-300.
- Ducharme FM, Davis GM. Measurement of respiratory resistance in the emergency department. Feasibility in young children with acute asthma. *Chest* 1997;111:1519-25.
- Duiverman EJ, Neijens HJ, van Strik R, van der Snee-van Smaalen M, Kerribijn KF. Bronchial responsiveness in asthmatic children aged 3 to 8 years measured by forced pseudo-random noise oscillometry. *Bull Eur Physiopathol Respir* 1986;22:27-34.
- Vink GR, Arets HGM, van der Laag J, van der Ent CK. Impulse oscillometry: a measure for airway obstruction. *Pediatr Pulmonol* 2003;35:214-9.
- Hellinckx J, De Boeck K, Bande-Knops J, van der Poel M, Demedts M. Bronchodilator response in 3-6.5 years old healthy and stable asthmatic children. *Eur Respir J* 1998;12:438-43.
- Sorkness CA, Lemanske RF Jr, Mauger DT, Boehmer SJ, Chinchilli VM, Martinez FD, et al. Long-term comparison of 3 controller regimens for mild-to-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. *J Allergy Clin Immunol* 2007;119:64-72.
- American Thoracic Society Committee of Proficiency Standards for Clinical Pulmonary Function Laboratories. Standardization of spirometry, 1994 update. *Am J Respir Crit Care Med* 1995;152:1107-36.
- Childhood Asthma Management Program. *Childhood Asthma Management Program spirometry manual, Version 3.0*. Springfield (VA): National Technical Information Service; 1994.
- Eigen H, Bieler H, Grant D, Christoph K, Terrill D, Heilman DK, et al. Spirometric pulmonary function in healthy preschool children. *Am J Respir Crit Care Med* 2001;163:619-23.
- Arets HGM, Brackel HJL, van der Ent CK. Forced expiratory manoeuvres in children: do they meet ATS and ERS criteria for spirometry? *Eur Respir J* 2001;18:655-60.
- Wang X, Dockery DW, Wypij D, Fay ME, Ferris BG. Pulmonary function between 6 and 18 years of age. *Pediatr Pulmonol* 1993;15:75-88.
- Childhood Asthma Management Program. *Childhood Asthma Management Program for methacholine challenge testing, version 3.0*. Springfield (VA): National Technical Information Service; 1994.
- American Thoracic Society Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. Guidelines for methacholine and exercise challenge testing—1999. *Am J Respir Crit Care Med* 2000;161:309-29.
- American Thoracic Society. Recommendations for standardized procedures for the on-line and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide in adults and children—1999. *Am J Respir Crit Care Med* 1999;160:2104-17.
- Strunk RC, Szefer SJ, Phillips BR, Zeiger RS, Chinchilli VM, Larsen G, et al. Relationship of exhaled nitric oxide to clinical and inflammatory markers of persistent asthma in children. *J Allergy Clin Immunol* 2003;112:883-92.
- Childhood Asthma Management Program. *Childhood Asthma Management Program allergy and skin test manual, version 2.0*. Springfield (VA): National Technical Information Service; 1994.
- Mitchell H, Senturia Y, Gergen P, Baker D, Joseph C, McNiff-Mortimer K. Design and methods of the National Cooperative Inner-City Asthma Study. *Pediatr Pulmonol* 1997;24:237-52.
- Omar RZ, Wright EM, Turner RM, Thompson SG. Analyzing repeated measurements data: a practical comparison of methods. *Stat Med* 1999;18:1587-603.
- Bye MR, Kerstein D, Barsh E. The importance of spirometry in the assessment of childhood asthma. *Am J Dis Child* 1992;146:977-8.
- Fuhlbrigge AL, Kitch BT, Paltiel AD, Kuntz KM, Neumann PJ, Dockery DW, et al. FEV₁ is associated with risk of asthma attacks in a pediatric population. *J Allergy Clin Immunol* 2001;107:61-7.
- Spahn JD, Chemiack R, Paull K, Gelfand EW. Is forced expiratory volume in one second the best measure of severity in childhood asthma? *Am J Respir Crit Care Med* 2004;169:784-6.
- Paull K, Covar R, Jain N, Gelfand EW, Spahn JD. Do NHLBI lung function criteria apply to children? A cross-sectional evaluation of childhood asthma at National Jewish Medical and Research Center, 1999-2002. *Pediatr Pulmonol* 2005;39:311-7.
- Wagner EM, Liu MC, Weinmann GG, Permutt S, Bleecker ER. Peripheral lung resistance in normal and asthmatic subjects. *Am Rev Respir Dis* 1990;141:584-8.
- Jain N, Covar RA, Gleason MC, Newell JD Jr, Gelfand EW, Spahn JD. Quantitative computed tomography detects peripheral airway disease in asthmatic children. *Pediatr Pulmonol* 2005;40:211-8.
- Frei J, Julia J, Kramer G, Hatzakis GE, Ducharme FM, Davis GM. Impulse oscillometry. Reference values in children 100 to 150 cm in height and 3 to 10 years of age. *Chest* 2005;128:1266-73.
- Zeiger RS, Szefer SJ, Phillips BR, Schatz M, Martinez FD, Chinchilli VM, et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. *J Allergy Clin Immunol* 2006;117:45-52.
- Szefer SJ, Phillips B, Martinez FD, Chinchilli VM, Lemanske RF Jr, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. *J Allergy Clin Immunol* 2005;115:233-42.

34. Evans TM, Rundell KW, Beck KC, Levine AM, Baumann JM. Airway narrowing measured by spirometry and impulse oscillometry following room temperature and cold temperature exercise. *Chest* 2005;128:2412-9.
35. Goldman MD, Carter R, Klein R, Fritz G, Carter B, Pachucki P. Within- and between-day variability of respiratory impedance, using impulse oscillometry in adolescent asthmatics. *Pediatr Pulmonol* 2002;34:312-9.
36. Guilbert TW, Morgan WJ, Zeiger RS, Mauger DT, Boehmer SJ, Szefer SJ, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. *N Engl J Med* 2006;354:1985-97.
37. Larsen GL, Kang J-KB, Guilbert T, Morgan W. Assessing respiratory function in young children: developmental considerations. *J Allergy Clin Immunol* 2005; 115:657-66.

TABLE E1. Slope for XA from 12 to 48 weeks of treatment for subsets of subjects

Treatment	Population	Estimate (95% CI)	<i>P</i> value
Fluticasone	All subjects	−0.656 (−1.008 to −0.303)	.0003
	eNO >25 ppb	−0.692 (−1.067 to −0.317)	.0003
	eNO ≥25 ppb	−0.606 (−1.209 to −0.004)	.0490
	Skin tests (−)	−0.766 (−1.305 to −0.227)	.0058
	Skin tests (+)	−0.620 (−1.040 to −0.200)	.0039
	Eosinophils <4%	−0.622 (−1.250 to 0.006)	.0528
	Eosinophils ≥4%	−0.683 (−1.112 to −0.254)	.0019
	PC ₂₀ >2.0	−0.899 (−1.439 to −0.359)	.0012
	PC ₂₀ ≤2.0	−0.542 (−0.990 to −0.093)	.0181